Marksans Pharma Expands European Reach with Acquisition of Netherlands-Based QliniQ B.V.
Advertisement
Marksans Pharma will acquire 100% of the share capital of QliniQ B.V. through a cash transaction valued at EUR 7.5 Mn.
Marksans Pharma, Mumbai, has entered the Dutch healthcare market through the acquisition of Netherlands-based QliniQ B.V., a pharmaceutical company with established sales, distribution, and market-access capabilities, further strengthening its European expansion strategy.
The transaction is expected to enhance Marksans Pharma’s market-access capabilities across regulated European markets while providing a direct platform for future product commercialization in the European Union.
Under the definitive agreement, Marksans Pharma will acquire 100% of the share capital of QliniQ B.V. through a cash transaction valued at EUR 7.5 Mn.
Commenting on the transaction, Mark Saldanha, Chairman and Managing Director of Marksans Pharma, said, “This acquisition represents an important strategic step in expanding Marksans’ presence across regulated European markets. It provides Marksans with direct access to the Netherlands market and enhances our ability to commercialize existing and future products across regulated European markets.”
Based in Mumbai, Marksans Pharma operates across major international markets, including the United States, Europe, Australia, and New Zealand. While QliniQ B.V., headquartered in Oldenzaal, the Netherlands, focuses on the commercialization and distribution of prescription medicines and medical devices.
Albert de Bruin and Raymond Lansink, Board Members and Shareholders of QliniQ B.V., said that Marksans’ strong product development capabilities, expanding portfolio and high-quality manufacturing expertise make it an ideal partner for the next phase of growth.
QliniQ maintains long-standing relationships with wholesalers, pharmacies, hospitals, and insurer-led tender channels across the Netherlands. It also provides access to EU GDP-compliant warehousing, regulatory capabilities, and multiple routes to market, including direct-to-consumer channels.
Stay tuned for more such updates on Digital Health News
